BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Chemistry & Biochemistry - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chemistry & Biochemistry
X-ORIGINAL-URL:/chemistry
X-WR-CALDESC:Events for Chemistry & Biochemistry
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260213T150000
DTEND;TZID=America/Chicago:20260213T160000
DTSTAMP:20260418T091621
CREATED:20260129T231753Z
LAST-MODIFIED:20260206T165814Z
UID:10003970-1770994800-1770998400@uwm.edu
SUMMARY:Colloquium\, Faija Akter\, 51ÁÔÆæ Chemistry
DESCRIPTION:Molybdenum Cofactor Deficiency: From Molecular Mechanisms to Clinical Breakthroughs\n\nMolybdenum cofactor (Moco) deficiency (MoCD) is a rare autosomal recessive disorder characterized by neonatal-onset myoclonic epileptic encephalopathy and dystonia\, with cerebral MRI changes resembling hypoxic–ischemic lesions. The molecular basis of the disease is the loss of sulfite oxidase (SOX) activity\, one of four Moco-dependent enzymes in humans. Accumulating toxic sulfite causes a secondary increase of metabolites such as S-sulfocysteine (SSC) and thiosulfate\, as well as a decrease in cysteine and its oxidized form\, cystine. These biochemical derangements trigger neurodegeneration through NMDA receptor-mediated excitotoxicity and ferroptosis resulting from glutathione depletion.\n\nMoco is synthesized by a three-step biosynthetic pathway involving the gene products of MOCS1\, MOCS2\, MOCS3\, and GPHN. Depending on which synthetic step is impaired\, MoCD is classified as type A\, B\, or C. This distinction is clinically relevant because the metabolic block in MoCD type A can be circumvented by administering cPMP\, marketed as fosdenopterin (Nulibry)\, which received FDA approval in 2021. Substitution therapy with cPMP is highly effective in reducing sulfite toxicity and restoring biochemical homeostasis\, while clinical outcome critically depends on the degree of brain injury prior to the start of treatment. Notably\, recent case studies reveal that brain injury begins prenatally between 22-28 weeks gestation\, underscoring the need for prenatal intervention strategies.\n\nIn the absence of specific treatments for MoCD type B/C and isolated SOX deficiency\, this presentation summarizes recent progress in understanding the underlying metabolic changes in cysteine homeostasis and explores novel therapeutic interventions — including dietary restriction\, NMDA receptor antagonists\, sulfite scavenging\, and ferroptosis inhibition to circumvent these pathological changes.
URL:/chemistry/event/colloquium-faija-akter-uwm-chemistry/
LOCATION:Chemistry Lecture Hall 110\, 2000 E. Kenwood Boulevard\, Milwaukee\, WI\, 53211\, United States
CATEGORIES:Colloquium
X-TRIBE-STATUS:
END:VEVENT
END:VCALENDAR